DOI vs Ibogaine
A side-by-side research comparison of DOI and Ibogaine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | DOI | Ibogaine |
|---|---|---|
| Full name | 2,5-Dimethoxy-4-iodoamphetamine | Ibogaine (from Tabernanthe iboga) |
| Category | Psychedelics | Psychedelics |
| Status | Schedule I (research compound) | Schedule I (research compound) |
| Mechanism | A potent, long-acting 5-HT2A receptor agonist; a standard pharmacology research tool. | Acts on multiple systems at once, including serotonin and opioid receptors, NMDA receptors and nicotinic receptors. Its active metabolite noribogaine is thought to drive much of the lasting anti-addiction effect. |
| Molecular weight | 321.16 g/mol | 310.43 g/mol |
| Half-life | Long | ~4-7 hours (ibogaine); noribogaine much longer |
| Bioavailability | Oral | Oral |
| Typical dose | Varies by individual and setting | Weight-based, given in specialized clinics |
| Frequency | Occasional | Usually a single session |
| Route | Oral | Oral, under medical and cardiac monitoring |
DOI reported benefits
- Key laboratory research tool
- Long-acting psychedelic
- Used to map 5-HT2A receptors
- DOx family
Ibogaine reported benefits
- Studied for opioid use disorder
- Can reduce withdrawal symptoms quickly
- May lower cravings after a single session
- Investigated for traumatic brain injury (with magnesium) in veterans
Related comparisons
Research and educational reference only. Not medical advice.